MYCN and neuroblastoma: Taken together, our study provided convincing data supporting the concept that combining BET bromodomain inhibition JQ1 with immune checkpoint blockade based on PD-1 offers a promising therapeutic approach for high-risk neuroblastoma displaying MYCN amplification.